{
    "organizations": [],
    "uuid": "d8c475f619d9050de22994ccb1a6356f9f44abb3",
    "author": "",
    "url": "https://www.reuters.com/article/brief-dar-bioscience-enters-into-agreeme/brief-dar-bioscience-enters-into-agreement-to-license-sst-6007-a-potential-treatment-for-fsad-idUSASB0C568",
    "ord_in_thread": 0,
    "title": "BRIEF-Daré Bioscience Enters Into Agreement To License SST-6007, A Potential Treatment For FSAD",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 11 PM / in 8 minutes BRIEF-Daré Bioscience Enters Into Agreement To License SST-6007, A Potential Treatment For FSAD Reuters Staff 1 Min Read \nFeb 12 (Reuters) - Dare Bioscience Inc: \n* DARÉ BIOSCIENCE, INC. ENTERS INTO LICENSE AND COLLABORATION AGREEMENT FOR A PRODUCT WITH THE POTENTIAL TO RECEIVE THE FIRST FDA APPROVAL FOR FEMALE SEXUAL AROUSAL DISORDER \n* DARE BIOSCIENCE INC - ‍ENTERED INTO AN AGREEMENT TO LICENSE SST-6007​ \n* DARE BIOSCIENCE INC - ‍DARÉ ANTICIPATES COMMENCING A PHASE 2B CLINICAL TRIAL IN SECOND HALF OF 2018 FOR SST-6007​ Source text for Eikon:  ",
    "published": "2018-02-12T15:08:00.000+02:00",
    "crawled": "2018-02-12T15:26:40.028+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "bioscience",
        "enters",
        "agreement",
        "license",
        "potential",
        "treatment",
        "fsad",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "dare",
        "bioscience",
        "inc",
        "daré",
        "bioscience",
        "enters",
        "license",
        "collaboration",
        "agreement",
        "product",
        "potential",
        "receive",
        "first",
        "fda",
        "approval",
        "female",
        "sexual",
        "arousal",
        "disorder",
        "dare",
        "bioscience",
        "inc",
        "agreement",
        "license",
        "dare",
        "bioscience",
        "inc",
        "anticipates",
        "commencing",
        "phase",
        "2b",
        "clinical",
        "trial",
        "second",
        "half",
        "source",
        "text",
        "eikon"
    ]
}